Patents by Inventor John M. Maraganore

John M. Maraganore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200239890
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Application
    Filed: November 11, 2019
    Publication date: July 30, 2020
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Publication number: 20200231968
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: November 4, 2019
    Publication date: July 23, 2020
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20200056175
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Application
    Filed: March 29, 2019
    Publication date: February 20, 2020
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Patent number: 10501740
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: December 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Patent number: 10273478
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Publication number: 20180127749
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 14, 2017
    Publication date: May 10, 2018
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20180066255
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Application
    Filed: July 6, 2017
    Publication date: March 8, 2018
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Patent number: 9725718
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: August 8, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Publication number: 20170121709
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 18, 2016
    Publication date: May 4, 2017
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Patent number: 9441225
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: September 13, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20160024499
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 28, 2016
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Patent number: 9068184
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5?-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2?-deoxy-2?-fluoro modified nucleotide, a 2?-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2?-amino-modified nucleotide, 2?-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: June 30, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Publication number: 20140363469
    Abstract: The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microRNA binding sites within the viral target sequence of the pathogen.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 11, 2014
    Inventors: Rachel Meyers, Brian Bettencourt, Jamie Evan Wong, John M. Maraganore
  • Publication number: 20140206747
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: January 14, 2014
    Publication date: July 24, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20140154783
    Abstract: The present invention relates to molecular biology, molecular genetics, and bioprocessing. The embodiments provide for compositions and methods for producing a biological product, such as an immunogenic agent, in an embryonated egg by introducing into the egg a RNA effector molecule capable of modulating expression of a target gene, wherein the modulation enhances production of the biological product in the egg. These methods provide for RNAi-based approaches to optimize the production of biologics from embryonated eggs, such as the production of viral vaccines including seasonal and pandemic flu vaccines. The invention also relates to molecules, reagents, cells, and kits useful for carrying out the methods, and biological products produced by the methods.
    Type: Application
    Filed: July 6, 2010
    Publication date: June 5, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, David Kocisko, Muthiah Manogaran, Todd Borland, Shannon Hogan
  • Publication number: 20140142162
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5?-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2?-deoxy-2?-fluoro modified nucleotide, a 2?-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2?-amino-modified nucleotide, 2?-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides.
    Type: Application
    Filed: June 21, 2012
    Publication date: May 22, 2014
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • Publication number: 20140099666
    Abstract: The invention provides compositions and methods for producing a biological product from a host cell. In various embodiments, the biological product is a polypeptide, a metabolite, a nutraceutical, a chemical intermediate, a biofuel, a food additive, or an antibiotic. In one aspect, the invention provides for a method for producing a biological product from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the biological product from the cell, and isolating the biological product from the cell.
    Type: Application
    Filed: July 6, 2010
    Publication date: April 10, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, David Kocisko, Muthiah Manoharan, Gregory Hinkle, Brian Bettencourt, Shannon Hogan
  • Patent number: 8658782
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: February 25, 2014
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20130164329
    Abstract: The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided.
    Type: Application
    Filed: February 16, 2011
    Publication date: June 27, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, Muthiah Manoharan
  • Publication number: 20110130443
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 2, 2011
    Inventors: Hans-Peter Vornlocher, John M. Maraganore